Overview
Hyloris Pharmaceuticals operates with a management team including Chairman Stefan Yee, who brings over 35 years of experience in corporate finance, M&A, and governance. The company maintains investor relations, governance structures, and a product portfolio organized into categories including Mavericks, Core Drivers, and Promising Seeds.
Key people
In the news
- Today we rang the opening bell at Euronext Brussels. Our CEO stijn van rompay opened the market this morning, in presence of Hyloris staff to celebrate with him. He was joined by Benoît van den Hove, CEO of @Euronext Brussels, and Pierre Davoust, CEO of @Euronext Securities. The occasion: Hyloris Pharmaceuticals SA is the first Belgian-headquartered company to adopt Euronext Securities’ new European Central Securities Depository (CSD) model. What it brings 👇 🌍 Greater visibility among European investors 🔍 More complete and
- Milan ✔️ Meetings ✔️ Momentum ✔️ #CPHIMilan 2026 is a wrap, and it was a fruitful one for our team. We connected with partners and peers from across the global pharma industry. Several promising opportunities are now on the table, and we're excited to keep building on them. 🤝 Our focus hasn't changed. We reinvent existing medicines through reformulation, repurposing and new chemical entities, using established regulatory pathways to deliver value faster. 💊 We're back in the office with a full follow-up list. 🔗 More on what we
- Today, Hyloris Pharmaceuticals's CEO stijn van rompay takes our H1 2026 results to investors at the European Midcap Event in Paris. 🗼 Our message is execution. Revenue grew 56%. Operating income grew 47%. Net loss narrowed to €1.9 million, the lowest for any half-year since our IPO. Our company model hasn't changed: reformulate and repurpose existing medicines along established regulatory pathways, and partner to extend their reach. 💊 RTU Pantoprazole IV (gastro) is now licensed to Orion for Europe. 🩸 Tranexamic Acid IV RTU
- Our business model at work! One formulation. A growing network of partners. 🌍 Maxigesic® IV, the non-opioid IV analgesic we developed with AFT Pharmaceuticals, is commercialized in multiple markets through a network of partners. Now Japan joins the list. AFT has signed an exclusive agreement with MIKASASEIYAKU Co., Ltd., a Tokyo-based specialty pharma company focused on orthopaedics, pain and inflammation. Mikasa will lead registration and commercialization in Japan. AFT remains responsible for supply. 🧪 The formulation:
- Consolidated 2026 Half-Year Results and Outlook Hyloris Pharmaceuticals: Our H1 2026 results, in three numbers and three moves. 📊 * Revenue growth 56% to €4.7M, * Operating income rose 47% to €5.6M, * and our HY Net Loss narrowed to €1.9M – our lowest half-year loss since IPO. Behind the numbers, advances on Hyloris' Mavericks, Core Drivers and Promising Seeds: * a new European license for ready-to-use Pantoprazole IV 🌿 with Orion, * a new exclusive license for Maxigesic® IV in China with AFT Pharmaceuticals, and * strong
- Today, it’s WORLD PATIENT SAFETY DAY! ✅ Safety at the heart of our DNA 💚 For us at Hyloris Pharmaceuticals, it's a chance to talk about how our reformulation and repurposed medicines contribute to our DNA. A great example from our product pipeline with Maxigesic® IV: Recovery shouldn't come with unnecessary opioid exposure. Maxigesic® IV, sold in the U.S. as Combogesic® IV combines paracetamol and ibuprofen in one non-opioid infusion for post-operative pain. Clinical studies showed faster relief than either medicine alone, with
- Yes we can!💚
- Great to be part of this journey: We add value through reinventing existing medications for unmet patient needs worldwide 🫶🌎
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.